The bone marrow microenvironment supports growth and differentiation of normal hematopoietic cells and can contribute to malignant growth. Since myeloma cells localize and accumulate in bone marrow, it is important to understand the influence of the bone marrow microenvironment not only on the growth of the malignant cells, but also on the therapeutic response of myeloma cells. Growth factors such as interleukin-6 (IL-6) produced by bone marrow stromal cells can protect myeloma cells from glucocorticoid-induced apoptosis. We examined the effect of myeloma cells-bone marrow stromal cells interaction in vitro on several therapeutic treatments. An interleukin-6-dependent myeloma cell line ANBL6 was used and treated with dexamethasone, doxorubicin, and melphalan in the presence of bone marrow stromal cells. Stromal cells were able to protect ANBL6 from dexamethasone, but significantly enhanced the effect of doxorubicin and melphalan. IL-6-induced bcl-XL and cyclin D2 expression in ANBL6 cells, but dexamethasone was able to suppress both bcl-XL and cyclin D2 expression in ANBL6. Doxorubicin and melphalan were able to suppress bcl-XL expression only in the presence of IL-6. We also looked at the effect of activating mutations of N-ras in myeloma cells interacting with stromal cells on therapeutic responses. Surprisingly, ANBL6 N-ras shows significant resistance to all drugs used. Notably, the presence of stromal cells did not alter ANBL6 Nras cells' drug resistance. These results suggest both the bone marrow microenvironment and genetic alterations of myeloma cells can independently impact on therapeutic responses. Leukemia (2001) 15, 264-271.
Introduction
Malignant plasma cell localization and accumulation in the bone marrow (BM) is a hallmark of multiple myeloma (MM). 1 Combination chemotherapy (melphalan and prednisone; MP) has been used for about three decades with limited success in treating MM patients. 2, 3 Therapeutic adjunctives such as thalidomide and pamidronate that target the bone marrow microenvironment and are capable of suppressing myeloma growth have been used in addition to conventional chemotherapy. [4] [5] [6] These studies have shown an impressive response in patients over the conventional chemotherapy alone in reducing skeletal disease, controlling IL-6 production by bone marrow stroma in patients, or altering angiogenic properties in the bone marrow microenvironment. [4] [5] [6] [7] [8] Our previous studies on therapeutic responses of MM cell lines showed single genetic change in tumor cells could alter drug responses in vitro. 9 Activated ras in the ANBL6 cell line shows resistance to dexamethasone-induced apoptosis even in the absence of IL-6 and the U266 cell line stably transfected with wild-type p53 becomes less sensitive to doxorubicin-and melphalan-induced apoptosis. 9 However, these studies did not consider the potential effect of the stromal microenvironment, provided by either cell-cell/cell-matrix interactions or from stromal secreted factors. The potential effect of bone marrow stroma (BMS) is important because it has been suggested that BMS expresses adhesion molecules and secretes extracellular matrix for MM attachment, such as VCAM-1, fibronectin, collagens, etc. 10, 11 The microenvironment also produces an array of cytokines that support the growth of MM, such as IL-6, IL-8, GM-CSF, etc. 11, 12 A recent report suggested integrin/fibronectin interaction with MM cells results in protection against doxorubicin and melphalan in vitro in the absence of live bone marrow stromal cells. 13 Moreover, it has been demonstrated that malignant plasma cells interact with BMS resulting in up-regulation of IL-6 in vitro.
14 IL-6 is a multifunctional cytokine that induces terminal differentiation of normal B cells to antibody-producing cells. 15 However, IL-6, produced abundantly by BMS from MM patients, acts as a major growth factor for malignant plasma cells and protects these plasma cells from glucocorticoid-induced apoptosis. 7, 9, [16] [17] [18] Signaling pathways induced by IL-6 have been studied intensively including the two main pathways JAK/STAT and ras/MAPK. 19 Thus, there is building evidence that shows the importance of the microenvironment on MM therapeutic responses.
It is not known what effects BMS has on a variety of therapeutic agents. Indeed, Rowley et al 9 have shown IL-6 can augment doxorubicin-and melphalan-induced apoptosis. Our studies reported here incorporate bone marrow stromal microenvironment in evaluating therapeutic responses and examine how IL-6 from BMS affects expression of downstream signaling molecules. We have developed an in vitro co-culture system to allow us to look at MM/BM stromal cells interaction and its effect on therapeutic responses. Because IL-6 has been shown to be an important growth factor for myeloma cells, we chose to examine an IL-6 dependent myeloma cell line grown in the context of stromal cells. We observed distinct effects on dexamethasone, doxorubicin, and melphalan responses. We also examined the impact of wild-type and mutant ras on therapeutic response in the presence of BMS because such genetic heterogeneity may alter the impact of the cell-cell interactions.
Materials and methods

Cell lines and cell culture
Myeloma cell lines ANBL6 plxsn (ANBL6) and ANBL6 plxsn N-ras 12EE (ANBL6 ras) described previously were cultured in RPMI 1640 supplemented with 10% FCS, l-glutamine, penicillin-streptomycin at 37°C and 7% CO 2 .
20,21 IL-6 dependent line (ANBL6) was also supplemented with 0.5 ng/ml IL-6 (R&D Systems, Minneapolis, MN, USA) every 4 days. Bone 
Reagents
Dexamethasone and melphalan were purchased from Sigma (St Louis, MO, USA). Doxorubicin was obtained from Calbiochem (San Diego, CA, USA). Anti-IL-6 monoclonal antibodies were purchased from R&D Systems. Concentrations used in the experiments were determined by titration to give maximum responses with minimal doses.
Cytokine detection
Supernatants collected from BMSCs at day 0 of co-cultures were used to measure IL-6 produced from BMSCs by ELISA (carried out at University of Minnesota, Cytokine Reference Laboratory).
Therapeutic response analysis
Myeloma cells (6 × 10 5 cells/well) were seeded in six-well plates with or without confluent BMSC. Myeloma cells were allowed to adhere to BMSC in the presence of 10% FCS overnight before chemoreagents were added. In some cases, myeloma cells were cultured in transwells or cell culture inserts (Becton Dickinson Labware, Franklin Lakes, NJ, USA) separated physically from BMSC and which only allowed soluble factors exchange. 1 ng/ml of IL-6 or 10 g of anti-IL-6 antibodies was added once every 2 days to cells as indicated. 0.5 m dexamethasone, 350 nm doxorubicin, and 5 m melphalan were used in the experiments as indicated. Cells were collected at times indicated and used for RNase protection assays or for apoptosis and cell cycle analyses.
Analysis of apoptosis and cell cycle
2 × 10 5 myeloma cells (cultured alone or with or without attachment to BMSC) were collected. Pelleted cells were resuspended in 500 l of hypotonic solution (50 g/ml PI in 0.1% sodium citrate plus 0.1% Triton X-100) and incubated for at least 4 h at 4°C in the dark. Analysis of the nuclei (both apoptotic and intact) was performed using FACSCalibur (Becton Dickinson, Mountain View, CA, USA). Apoptotic nuclei were detected as a heterogeneous subdiploid population to the left of intact nuclei in G 0 -G 1 . Any changes in cell cycle distribution were also detected by the same method.
Leukemia Table 1 bcl-XL/bax ratio of ANBL6 and ANBL6 N-ras under different therapeutic treatments Ratio represents arbitrary numbers calculated based on the RNase protection assay data at 12-h time point after normalization to internal control L32.
RNase protection assay
Total cellular RNA from 3 × 10 5 cells (cultured in suspension alone, co-cultured with BMSC in transwell, or attached to BMSC in the presence or absence of therapeutic reagents and IL-6) was isolated using TRIzol Reagent (GIBCO, Grand Island, NY, USA). 8 g of total RNA from each sample were re-suspended in hybridization solution. Bcl-family and Cyclin family probe sets were synthesized and labeled with [ 32 P] UTP according to the manufacturer (Pharmingen, San Diego, CA, USA). According to the manufacturer's protocol, a specific amount of c.p.m. of labeled probe was added to each RNA sample. The hybridization was carried out at 56°C overnight. Samples were then RNase treated for 45 min at 30°C. Hybridized probes were extracted once with phenol:chloroform:isoamyl alcohol and precipitated with ice-cold ammonium acetate/ethanol for 30 min at 70°C. Precipitated hybridized samples were washed once in ice-cold 90% ethanol, air dried and re-suspended in 5 l 1× loading buffer and analyzed on a 5% polyacrylamide urea gel. Radioactivity on the dried gel was detected by phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). Expression levels of the genes were quantified by normalizing to GAPDH and L32 (large ribosomal subunit protein 32) expression.
Results
Effect of IL-6 and bone marrow stroma on dexamethasone response of ANBL6 MM cells
IL-6 has been reported to protect myeloma cells from glucocorticoid-induced apoptosis. 17 The IL-6-dependent ANBL6 myeloma cell line is protected from dexamethasone in the presence of IL-6. 9 When ANBL6 was co-cultured with bone marrow stroma, it was also protected from dexamethasone induced apoptosis (Figure 1 ). When 10 g of anti-IL-6 polyclonal antibodies were added to the co-cultures, the protective effect was reduced significantly (Figure 1 ). To investigate whether or not physical interaction is important in protecting dexamethasone-induced apoptosis, we used a transwell coculture system to look at MM cells with and without direct interaction to BM stroma (Figure 2 ). In the presence of 10 g of anti-IL-6 polyclonal antibodies, ANBL6 cells that physically interacted with bone marrow stroma showed greater protection compared to the cells not in direct contact with the stroma (in transwell) (Figure 2 ). In the absence of anti-IL-6,
Figure 1
Effect of dexamethasone on ANBL6 cells. ANBL6 was cultured alone or with bone marrow stromal cells. 0.5 m of dexamethasone was used in the absence or presence of 1 ng/ml of IL-6. Cell cycle distribution was analyzed by PI staining of nuclei followed by flow cytometry at day 2. 10 g of anti-IL-6 polyclonal antibodies were used as indicated to block stromal cell secreted IL-6. Percent apoptosis are indicated at the upper left corner of each histogram.
Figure 2
Effect of stromal contact on ANBL6 cells treated with dexamethasone. ANBL6 cells were cultured either in contact with stromal cells or without contact (transwell). 10 g of anti-IL-6 were added as indicated and cell cycle profile was determined by flow cytometry at day 2. Ethanol/acetic acid fixed stromal cells were used in co-culture and 1 ng/ml of IL-6 was added as indicated.
equal protection of the myeloma cells in contact or non-contact was seen. Mild fixation with 2% paraformaldehyde (or EtOH/HAc fixation) of the stromal cells, which allowed the preservation of cell surface molecules and extracellular matrix of the stroma, abrogated close to 90% of the protection from dexamethasone ( Figure 2) . However, addition of IL-6 into the fixed co-culture protected tumor cells from dexamethasoneinduced death. The percentage of ANBL6 cells adhered on fixed stroma was not greatly changed compared to co-culture with live stroma (50 to 80% of cells adhered, data not shown).
Effect of IL-6 and bone marrow stroma on the response of the ANBL6 MM cell line to doxorubicin treatment
To study how IL-6 or bone marrow stroma affect doxorubicin response of ANBL6 cells, we cultured ANBL6 in the absence or presence of 0.5 ng/ml of IL-6 and 350 nm of doxorubicin (see Materials and methods). We did not see a drastic difference in percent apoptosis in ANBL6 cells in the absence or presence of IL-6 at day 2 with 350 nm doxorubicin (Figure 3) .
Figure 3
Effect of doxorubicin on ANBL6 cells. ANBL6 was cultured alone or with bone marrow stromal cells. 350 nm of doxorubicin was used in the absence or presence of 1 ng/ml of IL-6 (upper), or in co-culture with stromal cells (lower). Cell cycle distribution was analyzed by flow cytometry at day 2 and 4. 10 g of anti-IL-6 polyclonal antibodies were used as indicated to block stromal cell secreted IL-6. Percent apoptotic cells are indicated.
However, there was a significant accumulation of ANBL6 cells at the G 2 /M phase at day 2 in the presence of IL-6 and doxorubicin. At day 4, the difference of percent apoptotic cells in the two conditions was obvious. IL-6 enhanced the sensitivity of ANBL6 cells to doxorubicin. The percent of cell death at day 4 increased from 15% to 70% with the addition of IL-6 ( Figure 3 ). Co-culturing ANBL6 with bone marrow stroma also enhanced the effectiveness of doxorubicin as early as day 2 ( Figure 3 ). This effect was significantly reduced when anti-IL-6 polyclonal antibodies were added to the co-culture. Notably the G 2 /M phase accumulation of ANBL6 cells was consistently observed when doxorubicin was added in the presence of IL-6 or with stromal cells. The ANBL6 cells were cultured in transwells with bone marrow stromal cells in the presence of anti-IL-6 polyclonal antibodies to study the effect of cell-cell contact on therapeutic response (Figure 4 ). Close
Figure 4
Effect of stromal contact on ANBL6 cells treated with doxorubicin. ANBL6 cells were cultured either in contact with stromal cells or without contact (transwell). 10 g of anti-IL-6 were added and cell cycle profiles at day 2 and day 4 were determined by flow cytometry. 1 ng/ml of IL-6 was added as indicated.
Leukemia contact between ANBL6 and stromal cells enhanced the effect of doxorubicin killing as shown in Figure 4 . When ANBL6 cells were not in direct contact with stromal cells (in the transwell), they were less sensitive. In addition, little accumulation of ANBL6 cells at G 2 /M phase was observed if they were cultured away from stromal cells (Figure 4) . Thus, instead of protecting myeloma cells as we observed with dexamethasone, stromal cells enhanced doxorubicin-induced cell cycle arrest and apoptosis.
Effect of activated N-ras mutation in ANBL6 when treated with dexamethasone and doxorubicin in the presence or absence of IL-6 or stromal cells
Genetic heterogeneity of MM has been shown to contribute to alterations of therapeutic response and can complicate the ANBL6 N-ras are resistant to dexamethasone. ANBL6 and ANBL6 N-ras were either cultured alone or with stromal cells. 1 ng/ml of IL-6 was added as indicated. Cells were stained with PI at day 2 and flow cytometry was used to determine cell cycle distribution. Percent of apoptotic cells are indicated.
design of appropriate treatments for individual patients. 22 Approximately 30-50% of MM patients have activated ras mutations in the malignant plasma cells. [23] [24] [25] Therefore we decided to look at how activated N-ras mutation would affect therapeutic response in our co-culture system. As previously shown by our laboratory, activated N-ras in ANBL6 also protects them from dexamethasone induced apoptosis ( Figure 5 ). Since activated N-ras has been shown to induce cell cycle of myeloma cells, 20, 21 we expected the combination of N-ras mutation and stroma would increase the sensitivity of tumor cells to DNA damaging drugs doxorubicin and melphalan. Surprisingly, ANBL6 stably transfected with activated N-ras showed significant protection to doxorubicin at day 4, even in the presence of BMS (Figure 6 ).
Figure 6
ANBL6 N-ras are resistant to doxorubicin. ANBL6 and ANBL6 N-ras were either cultured alone or with stromal cells. 1 ng/ml of IL-6 was added as indicated. Cells were stained with PI at day 2 and flow cytometry was used to determine cell cycle distribution. Percent of apoptotic cells are indicated.
Effect of therapeutic agents dexamethasone and doxorubicin on bcl family and cyclin family gene expression in ANBL6 and ANBL6 N-ras cell lines in the presence or absence of IL-6 or bone marrow stromal cells
Data from our co-culture results suggest that IL-6 produced from stromal cells appeared to be the dominant factor in therapeutic responses. When we blocked the IL-6 from BMS, ANBL6 cells no longer were protected from dexamethasone and the doxorubicin effect was greatly reduced. We examined a panel of bcl family genes by RNase protection assay. Among a panel of bcl family genes, IL-6 up-regulated bcl-XL expression rapidly (three fold increase in 4 h) in ANBL6 cell
Figure 7
Effect of IL-6 on bcl family and cyclin family genes in ANBL6 and ANBL6 N-ras cells. Total RNA was collected after the addition of 1 ng/ml IL-6 as indicated. 8 g of total RNA from each time point was used in the RNase protection assay. Relative expression level was determined by normalizing to internal controls, GAPDH and L32. line ( Figure 7) . Of the major cyclins, IL-6 seemed to augment the expression of only cyclin D2 in ANBL6 cells. Expression of other cyclin genes were insignificant compared to cyclin D2 expression (not shown). When activated N-ras was present in ANBL6 cells, IL-6 did not further augment the expression of bcl-XL and cyclin D2 (Figure 7) . In order to determine the effect of dexamethasone, doxorubicin and melphalan on bcl family and cyclin family genes expression, different therapeutic treatment conditions were used (Figure 8 ). Dexame-
Figure 8
Effect of IL-6 and therapeutic agents on bcl family and cyclin family genes in ANBL6 and ANBL6 N-ras cells. Total RNA was collected at 12 h after cells were treated at different conditions as indicated. 8 g of total RNA from each condition was used in the RNase protection assay. Relative expression level was determined by normalizing to internal controls, GAPDH and L32. 1 ng/ml of IL-6, 0.5 m of dexamethasone and 350 nm of doxorubicin were used as indicated.
Leukemia thasone suppressed bcl-XL and cyclin D2 expression in ANBL6, but IL-6 was able to augment their expression twofold in ANBL6 (Figure 8 ). Doxorubicin and melphalan treatments did not suppress bcl-XL and cyclin D2 expression. It is believed that bcl-X/bax ratio is important for cell survival. 26 Indeed, IL-6 was able to increase this ratio in ANBL6 cells (Table 1) . Interestingly, the combination of IL-6 and doxorubicin or melphalan lowered the bcl-XL/bax ratio in ANBL6, thus contributing to cell death as previously described (Table 1) .
Discussion
Malignant myeloma cells reside in the bone marrow microenvironment. 1 The bone marrow microenvironment provides adhesion molecules and extracellular matrix, such as VCAM and fibronectin, for anchorage. 10, 11 It also secretes cytokines, such as IL-6, and other soluble factors, for growth and survival for normal and tumor cells. 11, 12 It is known that extracellular matrix proteins are capable of regulating anchorage-dependent cell survival. 27 Specifically, fibronectin protected adherent myeloma cells from doxorubicin roughly two-fold better than the BSA controls. 13 In addition to matrix proteins, soluble factors are also important to maintain cell growth and regulate cell survival of the malignant plasma cells. Uchiyama et al 14 demonstrated that myeloma cells are capable of up-regulating IL-6 expression of bone marrow stromal cells. We and others have shown that exogenous IL-6 or IL-6 secreted from bone marrow stromal cells is capable of protecting malignant plasma cells from dexamethasone induced apoptosis. 9, 17, 18 The data in this report have shown the importance of bone marrow stromal cells in altering myeloma cells' therapeutic responses. Our studies investigated the impact of in vitro bone marrow stromal culture on therapeutic responses of the myeloma cell line ANBL6 and examined what impact IL-6 has on the expression of several bcl and cyclin family members.
As shown by us and by others, 18 stromal cells are known to protect dexamethasone induced apoptosis in myeloma cells. When IL-6 was depleted from the co-culture, protection against dexamethasone was significantly reduced. Similarly, when we gently fixed the stromal cells while preserving the cell surface molecules and extracellular matrix integrity, we were not able to observe a significant protective effect unless IL-6 was added (Figure 2 ). These results imply the protection provided by bone marrow stromal co-culture may be mainly due to the presence of IL-6. Interestingly, in the presence of anti-IL-6 antibodies, ANBL6 cells in contact with stromal cells did show some protection from dexamethasone ( Figure 2 ). However, it is possible that close contact with stroma provide a local low concentration of IL-6 and was taken up by ANBL6 cells immediately as it was secreted by stromal cells. Interestingly, bone marrow stroma do not protect myeloma cells from all therapeutic agents. In contrast to the protective effect on dexamethasone-induced apoptosis, BMS significantly enhanced doxorubicin killing presumably by pushing ANBL6 cells into cell cycle (Figure 4) . Similar results were observed with melphalan treatment (data not shown). IL-6 secreted by bone marrow stromal cells is able to drive myeloma cells into cell cycle. Thus proliferating myeloma cells likely become more sensitive to DNA damaging agents in the presence of IL-6. Anti-IL-6 eliminated the enhanced response of doxorubicin in ANBL6 in the presence of bone marrow stromal cells (Figure 3) .
Another aspect in our study showed how one genetic mutation could significantly alter the response of the myeloma cells to therapeutic treatment in the bone marrow microenvironment. IL-6 signals not only through JAK/STAT pathway but also through the ras/MAPK pathway. 19 Thirty to 50% of myeloma patients carry ras mutations, mostly N-ras mutation. [23] [24] [25] We generated the ANBL6 N-ras line by stably introducing the activated N-ras into the cells. 20 The result was a loss of IL-6 dependency and therapeutic resistance of the myeloma line. 20 Contrary to our expectation that activated Nras in ANBL6 and IL-6 from stroma would induce proliferative signal to the cells and cause the cells to become more sensitive to DNA damaging agents such as doxorubicin and melphalan, the ANBL6 N-ras cells showed significant resistance to dexamethasone, doxorubicin and melphalan (data not shown) treatments even in the presence of BMS (Figures 5 and  6 ). The mechanism for this is not clear, but may be due to the constitutive signaling activation that regulate anti-apoptotic responses such as bad/bcl-XL interaction. 28 From the co-culture results, IL-6 seemed to be the prominent contributor to the distinct therapeutic responses of the ANBL6 cells. To investigate the downstream effect of IL-6 and therapeutic agents, we used RNase protection assays to detect any changes in gene expression of bcl and cyclin families. Consistent with previous results, 29 bcl-XL was found to be upregulated by IL-6. The ratio of bcl-XL/bax in ANBL6 was augmented upon IL-6 stimulation ( Table 1) . Dexamethasone suppressed bcl-XL expression in the absence of IL-6 in ANBL6 and ANBL6 N-ras. Its expression level was rescued in ANBL6 cells when IL-6 was added. Doxorubicin was able to suppress bcl-XL level in the presence of IL-6 in both cell lines. Interestingly, when ANBL6 was treated with doxorubicin alone, bcl-XL expression was increased ( Figure 8 ). This is similar to the observation made previously that bcl-2 can be up-regulated in myeloma cells by exposure to doxorubicin. 30 Perhaps it may be one mechanism by which tumor cells acquire chemoresistance. However, IL-6 in this case was able to suppress bcl-XL in the presence of doxorubicin. And the bcl-XL suppression by IL-6 corresponds well to ANBL6 cell death in the presence of doxorubicin ( Figure 6 ). Cyclin D2 seemed to be the only cyclin expressed in high level in ANBL6 and ANBL6 N-ras. IL-6 was able to augment cyclin D2 level in ANBL6 cells, but not in ANBL6 N-ras cells. When dexamethasone was added, cyclin D2 levels went down, but was inducible in response to IL-6. Our RPA data showed that bcl-XL and cyclin D2 were not further induced by IL-6 in the ANBL6 Nras line (Figure 8 ), likely because of constitutive high expression. In other cell types, it has been shown that bcl-XL expression can be altered if MEK is blocked. 31, 32 This may suggest one of the roles of activated ras in tumor cell survival.
Recent data have suggested the importance of bone marrow microenvironment in the growth and survival of MM. 10, 13, 14, 18, 33 Adhesion interactions in the microenvironment have been shown to be important in myeloma cell survival under therapeutic treatment. 13 However, the IL-6 effect on ANBL-6 therapeutic responses was shown to be the dominant effect in our studies. In this report, we considered both adhesion interaction and soluble factors secreted by bone marrow stromal cells in vitro and determined how they contribute to therapeutic response of the ANBL-6 cells in an in vitro co-culture system. Our data along with others suggest that cell-cell interactions, growth factors, and genetic defects all contribute to the therapeutic response of myeloma cells.
